GlassScriptPhysician profile
Gregory Joseph Phillips
NPI 1699705152
$23,366.48
in general payments reported to CMS, 2019-2025
60 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,693 · 2020: $2,458 · 2021: $4,284 · 2022: $3,861 · 2023: $2,576 · 2024: $3,385 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,551 · Consulting Fee: $500 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,550.91 |
| Consulting Fee | $500.00 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,404.95 | 2019-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $2,102.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,090.72 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $1,939.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,628.87 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $1,283.74 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,083.68 | 2019-2025 | Jardiance |
| Abbvie INC. | $1,028.19 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $739.64 | 2019-2024 | Xifaxan, Trulance, Cycloset |
| Pfizer INC. | $530.37 | 2019-2025 | |
| Amarin Pharma, INC. | $508.50 | 2019-2021 | |
| Mylan Specialty L.P. | $497.79 | 2019-2024 | Yupelri, Yupelri |
| Sunovion Pharmaceuticals INC. | $455.78 | 2019-2022 | |
| Allergan, INC. | $455.25 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $421.18 | 2021-2025 | Rexulti |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $400.85 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $395.92 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $365.64 | 2021-2024 | |
| Esperion Therapeutics, INC. | $352.84 | 2020-2024 | Nexletol, Nexlizet |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.01 | 2022-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $328.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $312.33 | 2019-2023 | Camzyos |
| Gilead Sciences, INC. | $285.12 | 2019-2025 | Yeztugo |
| Almatica Pharma LLC | $271.62 | 2021-2024 | Loreev Xr |
| Phathom Pharmaceuticals, INC. | $270.78 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $256.60 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Axsome Therapeutics, INC. | $236.93 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $221.78 | 2020-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $212.77 | 2021-2025 | |
| Abbott Laboratories | $186.24 | 2019-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $175.73 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $141.14 | 2019-2021 | |
| Eisai INC. | $140.79 | 2020-2021 | |
| Lundbeck LLC | $135.63 | 2021-2025 | Rexulti |
| Portola Pharmaceuticals, LLC | $124.99 | 2019 | |
| Kite Pharma, INC. | $100.05 | 2024 | Yescarta |
| Sumitomo Pharma America, INC. | $96.51 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $88.14 | 2019-2021 | |
| Daiichi Sankyo INC. | $71.86 | 2021 | |
| Azurity Pharmaceuticals, INC. | $66.53 | 2025 | Edarbi |
| Viatris Specialty LLC | $61.99 | 2025 | Yupelri |
| Ironwood Pharmaceuticals, INC | $59.62 | 2019-2020 | |
| Exact Sciences Corporation | $48.07 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Althera Pharmaceuticals LLC | $44.60 | 2021-2022 | |
| Genentech USA, INC. | $42.57 | 2019-2021 | |
| Zealand Pharma US, INC. | $38.50 | 2022 | |
| Protega Pharmaceutials INC | $34.91 | 2023 | Roxybond |
| Nestle Healthcare Nutrition INC. | $34.78 | 2021-2022 | |
| Vivus LLC | $32.88 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $32.43 | 2023 | Quviviq |
| Ibsa Pharma INC. | $31.93 | 2022-2025 | Tirosint, Flector, Licart |
| Shire North American Group INC | $26.70 | 2019 | |
| Corcept Therapeutics | $25.92 | 2023 | Korlym |
| Halozyme INC | $16.25 | 2023 | |
| Aytu Biopharma, INC. | $16.17 | 2020 | |
| Beta Bionics, INC. | $16.11 | 2024 | Ilet Bionic Pancreas |
| Insulet Corporation | $14.59 | 2019 | |
| Mannkind Corporation | $13.67 | 2022 | |
| Clarus Therapeutics INC. | $13.24 | 2021 | |
| Medtronic, INC. | $13.20 | 2023 | Closurefast |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.